A 48-week update of a multicentre real-life experience of dupilumab in adult patients with moderate-to-severe atopic dermatitis

J Dermatolog Treat. 2022 Mar;33(2):1146-1149. doi: 10.1080/09546634.2020.1773379. Epub 2020 Jul 3.
No abstract available

Publication types

  • Letter
  • Multicenter Study

MeSH terms

  • Adult
  • Antibodies, Monoclonal, Humanized / therapeutic use
  • Dermatitis, Atopic* / drug therapy
  • Eczema*
  • Humans
  • Severity of Illness Index
  • Treatment Outcome

Substances

  • Antibodies, Monoclonal, Humanized
  • dupilumab